Financial Results
Chemiesynth Board Approves Q2 FY27 Results
Chemiesynth (Vapi) Ltd approved unaudited financial results for the quarter and half year ended 30 September 2026, along with the statutory auditor’s limited review report.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
6
Neutral
5
Bullish
3
Bearish
6
Neutral
21
Bullish
19
Bearish
0
Neutral
16
Bullish
16
Bearish
0
Neutral
16
Bullish
16
Bearish
0
Neutral
16
Bullish
16
Bearish
0
Neutral
16
Bullish
16
Chemicals & Petrochemicals
Specialty Chemicals
47 Cr
Low Risk
0.0
34.8
—
4.7
160.70
39.51
Sales CAGR
Profit CAGR
ROE
ROCE
Chemiesynth (Vapi) Ltd (CHEMIESYNT) is currently trading at 160.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Chemiesynth (Vapi) Limited is a custom manufacturer of organic and specialty chemicals, established in April 1986, operating two production sites in Vapi, Gujarat, and supplying global agrochemical, pharmaceutical, photographic and cosmetics companies with both contract manufacturing assets and services including process optimization and scale-up for volumes ranging from kilos to several hundred tons. The Board approved unaudited financial results for the quarter and nine months ended 31 December 2025 at its meeting on 13 February 2026, and the statutory auditor completed a limited review with an unqualified report; the company reported a materially larger loss of Rs. 159.29 lakh for the nine months ended 31 December 2025 versus a Rs. 29.47 lakh loss in the prior period. Operationally focused on dye intermediates and specialty chemicals, Chemiesynth positions itself as a flexible custom manufacturer able to handle varied batch sizes and unit operations, offering both asset-backed contract manufacturing and technical services that support process scale-up and optimization for international clients. The company faces clear margin pressure reflected in widening losses for the latest nine-month period, while having export exposure and long-tenured manufacturing capabilities that present opportunities to deepen contract manufacturing wins, improve utilization, and pursue margin recovery through pricing, cost controls, or targeted product-mix shifts.
Over the past 52 weeks, Chemiesynth (Vapi) Ltd has traded between a low of ₹39.51 and a high of ₹160.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Chemiesynth (Vapi) Ltd has a market capitalization of approximately 46.99. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Chemiesynth (Vapi) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 46.99 Cr, Chemiesynth (Vapi) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Chemiesynth (Vapi) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Chemiesynth (Vapi) Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Financial Results
Chemiesynth (Vapi) Ltd approved unaudited financial results for the quarter and half year ended 30 September 2026, along with the statutory auditor’s limited review report.
Board Meeting
Chemiesynth (Vapi) Ltd will hold a Board meeting on 4 November 2026 to consider unaudited financial results for the quarter and half year ended 30 September 2026.